The 1-year follow-up results of intraprocedural valve-in-valve deployment for treatment of aortic regurgitation following transcatheter aortic valve replacement (TAVR) in a single center
- VernacularTitle:经导管主动脉瓣置换术（TAVR）中同期行瓣中瓣置入术的单中心一年期临床随访结果
- Author:
Weijing ZHANG
1
;
Wenzhi PAN
1
;
Lihua GUAN
1
;
Xiaochun ZHANG
1
;
Yuan ZHANG
1
;
Jian WU
2
;
Wei LI
3
;
Cuizhen PAN
3
;
Daxin ZHOU
1
;
Junbo GE
1
Author Information
1. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P.R.China
2. Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, P.R.China
3. Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, 200032, P.R.China
- Publication Type:Journal Article
- Keywords:
Transcatheter aortic valve replacement (TAVR);
intraprocedural valve-in-valve deployment;
perivalvular leakage
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(08):888-894
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficiency and safety of intraprocedural valve-in-valve deployment for treatment of aortic regurgitation following transcatheter aortic valve replacement (TAVR). Methods Consecutive patients (n=333) who diagnosed with severe aortic stenosis and underwent TAVR in Zhongshan Hospital affiliated to Fudan University from October 3rd, 2010 to April 21st, 2021 were included. There were 208 males and 125 females aged 76.0±7.0 years. There were 316 patients underwent simple TAVR (simple TAVR group) and 17 patients underwent intraprocedural valve-in-valve deployment following TAVR (valve-in-valve group). Their clinical and echocardiographic outcomes were evaluated and compared. Results There was no significant difference between the two groups of patients at postoperative 30 d and 1 year in all-cause mortality (4.4% vs. 0, P=1.000; 6.3% vs. 0, P=1.000), incidence of pacemaker implantation (10.4% vs. 17.6%, P=1.000; 11.8% vs. 17.6%, P=1.000), incidence of ischemic stroke (1.3% vs. 0, P=1.000; 1.3% vs. 0, P=1.000), mean trans-aortic pressure gradient (11.4±6.4 mm Hg vs. 8.9±4.9 mm Hg, P=0.099; 10.5±7.6 mm Hg vs. 11.2±5.2 mm Hg, P=0.432), left ventricular ejection fraction (62.0%±9.0% vs. 57.0%±12.0%, P=0.189; 63.0%±7.0% vs. 60.0%±8.0%, P=0.170), and incidence of mitral valve dysfunction (0.6% vs. 5.9%, P=1.000; 0.6% vs. 5.9%, P=1.000). Conclusion It is feasible to treat perivalvular leakage with valve-in-valve technology in the procedure of TAVR, and the short and medium-term effects are satisfied.
